Treatment of idiopathic short stature: Effects of gonadotropin-releasing hormone analogs, aromatase inhibitors and anabolic steroids

Hormone Research in Paediatrics

Volumn 76, Issue SUPPL. 3, 2011, Pages 27-29

  Dunkel, Leo ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Anabolic steroids; Aromatase inhibitors; GnRH analogs; Linear growth; Short stature

Indexed keywords

ANABOLIC AGENT; ANASTROZOLE; AROMATASE INHIBITOR; FADROZOLE; GONADORELIN DERIVATIVE; LETROZOLE; OXANDROLONE; PLACEBO; SEX HORMONE; TESTOLACTONE;

ADOLESCENCE; CHILD GROWTH; CHILDHOOD DISEASE; CHRONIC DRUG ADMINISTRATION; CONFERENCE PAPER; DELAYED PUBERTY; DRUG RESEARCH; GROWTH PLATE; HORMONAL REGULATION; HUMAN; IDIOPATHIC DISEASE; PRIORITY JOURNAL; PUBERTY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT STATURE; TREATMENT DURATION;

ADOLESCENT; ANABOLIC AGENTS; AROMATASE INHIBITORS; BODY HEIGHT; CHILD; GONADOTROPIN-RELEASING HORMONE; GROWTH DISORDERS; HUMANS; PUBERTY;

EID: 80052742758     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000330150     Document Type: Conference Paper

References (25)

1. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056-1061 [Erratum, N Engl J Med 1995; 332: 131]. (Pubitemid 24317698)
2. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K: Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689-3698.
3. Weise M, De-Levi S, Barnes KM, Gafni RI, Abad V, Baron J: Effects of estrogen on growth plate senescence and epiphyseal fusion. Proc Natl Acad Sci USA 2001; 98: 6871-6876. (Pubitemid 32538309)
4. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr: Increased final height in precocious puberty after long-term treatment with LHRH agonists: The National Institutes of Health experience. J Clin Endocrinol Metab 2001; 86: 4711-4716. (Pubitemid 33020510)
5. Brauner R, Adan L, Malandry F, Zantleifer D: Adult height in girls with idiopathic true precocious puberty. J Clin Endocrinol Metab 1994; 79: 415-420. (Pubitemid 24256528)
6. Paul D, Conte FA, Grumbach MM, Kaplan SL: Long-term effect of gonadotropin- releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab 1995; 80: 546-551.
7. Vizmanos B, Martí-Henneberg C, Clivillé R, Moreno A, Fernandez- Ballart J: Age of pubertal onset affects the intensity and duration of pubertal growth peak but not final height. Am J Human Biol 2001; 13: 409-416. (Pubitemid 32401238)
8. Carel JC, Hay F, Coutant R, Rodrigue D, Chaussain JL: Gonadotropinreleasing hormone agonist treatment of girls with constitutional short stature and normal pubertal development. J Clin Endocrinol Metab 1996; 81: 3318-3322. (Pubitemid 26296209)
9. Bouvattier C, Coste J, Rodrigue D, Teinturier C, Carel JC, Chaussain JL, Bougnéres PF: Lack of effect of GnRH agonists on final height in girls with advanced puberty: A randomized long-term pilot study. J Clin Endocrinol Metab 1999; 84: 3575-3578. (Pubitemid 30645208)
10. Lanes R, Gunczler P: Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Clin Endocrinol (Oxf) 1998; 49: 197-202. (Pubitemid 28372648)
11. Yanovski JA, Rose SR, Municchi G, Pescovitz OH, Hill SC, Cassorla FG, Cutler GB Jr: Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med 2003; 348: 908-917. (Pubitemid 36300762)
12. Mericq MV, Eggers M, Avila A, Cutler GB Jr, Cassorla F: Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone-releasing hormone analog: Results of a prospective, randomized trial. J Clin Endocrinol Metab 2000; 85: 569-573. (Pubitemid 32273636)
13. Pasquino AM, Pucarelli I, Roggini M, Segni M: Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J Clin Endocrinol Metab 2000; 85: 619-622. (Pubitemid 32273643)
14. Mul D, Wit JM, Oostdijk W, Van den Broeck J, Dutch Advisory Group on Growth Hormone: The effect of pubertal delay by GnRH agonist in GH-deficient children on final height. J Clin Endocrinol Metab 2001; 86: 4655-4656. (Pubitemid 33020503)
15. van Gool SA, Kamp GA, Visser-van Balen H, Mul D, Waelkens JJ, Jansen M, Verhoeven-Wind L, Delemarre-van de Waal HA, de Muinck Keizer-Schrama SM, Leusink G, Roos JC, Wit JMJ: Final height outcome after three years of growth hormone and gonadotropin-releasing hormone agonist treatment in short adolescents with relatively early puberty. Clin Endocrinol Metab 2007; 92: 1402-1408. (Pubitemid 46556417)
16. Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB Jr: Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999; 84: 175-178. (Pubitemid 29036697)
17. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB Jr: Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000; 85: 1114-1120. (Pubitemid 32269358)
18. Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L: A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: A randomised controlled trial. Lancet 2001; 357: 1743-1748. (Pubitemid 32524203)
19. Hero M, Norjavaara E, Dunkel L: Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: A randomized controlled trial. J Clin Endocrinol Metab 2005; 90: 6396-6402. (Pubitemid 41759291)
20. Hero M, Wickman S, Dunkel L: Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 2006; 64: 510-513.
21. Dunkel L: Update on the role of aromatase inhibitors in growth disorders. Horm Res 2009; 71: 57-63.
22. Schroor EJ, van Weissenbruch MM, Knibbe P, Delemarre-van de Waal HA: The effect of prolonged administration of an anabolic steroid (oxandrolone) on growth in boys with constitutionally delayed growth and puberty. Eur J Pediatr 1995; 154: 953-957.
23. Tse WY, Buyukgebiz A, Hindmarsh PC, Stanhope R, Preece MA, Brook CGD: Long-term outcome of oxandrolone treatment in boys with constitutional delay of growth and puberty. J Pediatr 1990; 117: 588-591. (Pubitemid 20332101)
24. Wickman S, Dunkel L: Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys: Evidence for a pituitary site of action of endogenous E. J Clin Endocrinol Metab 2001; 86: 4887-4894. (Pubitemid 33020537)
25. Lampit M, Hochberg Z: Androgen therapy in constitutional delay of growth. Horm Res 2003; 59: 270-275. (Pubitemid 36649382)